Navigation Links
Peptimmune Initiates Phase Ib Study of PI-2301 in Multiple Sclerosis Patients and Presentation at BIO 2008
Date:6/17/2008

ism of action for PI-2301, and dose-dependent pharmacokinetics was observed.

PI-2301 has been optimized using Peptimmune's novel platform peptide chemistry and, in preclinical studies, has shown to be more potent and effective than Copaxone in treating disease models for multiple sclerosis. PI-2301 has also shown efficacy in preclinical models of autoimmune diseases where immune modulation may be effective, such as Crohn's disease, rheumatoid arthritis, and autoimmune uveitis. Peptimmune has put in place high-quality synthesis and analytical methods that provide a superior level of batch-to- batch reproducibility in the manufacturing of PI-2301.

Over 400,000 Americans have multiple sclerosis (MS), and MS may affect over 2.5 million individuals worldwide. MS is an autoimmune disease in which the individuals' immune system responds against multiple components of nerve- insulating myelin. The effects of these immune-mediated attacks can range from relatively benign to somewhat disabling to devastating, as communication between the brain and other parts of the body is disrupted.

About Peptimmune

Peptimmune, Inc. is a privately held clinical stage biotechnology company focused on the development of peptide therapies to improve the management of chronic autoimmune and inflammatory disorders. The Company is in clinical development with second-generation therapeutics that are expected to result in safer and more effective products for multiple sclerosis and pemphigus vulgaris. Current investors include New Enterprise Associates, MPM Capital, Hunt Ventures, Boston Medical Investors, Silicon Valley Bank Capital, and Genzyme Corporation.

For additional information, please contact us.


'/>"/>
SOURCE Peptimmune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Peptimmune Presents Early Clinical Data at European Neurological Society and Federation of Clinical Immunology Societies Meetings
2. Peptimmune Completes Phase I Study with a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis
3. Peptimmune Initiates Phase I Study With a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis
4. Transdel Initiates Ketotransdel(TM) Phase 3 Clinical Program for Pain
5. Medivation Initiates Second Pivotal Phase 3 Trial of Dimebon(TM) in Patients With Alzheimers Disease
6. TorreyPines Therapeutics Initiates Clinical Trial to Evaluate Analgesic Effect of Oral Prodrug of Tezampanel
7. Nuvelo Initiates Phase 1B Clinical Trial of Anticoagulant NU172
8. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
9. Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer
10. Human Genome Sciences Initiates First Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Solid Tumors
11. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/p37spr/north_america ) has announced ... MRI Market - Growth, Trends And Forecasts (2014 - ... key players in the industry are GE , Hitachi ... Medical Systems MRI is a ... its higher sensitivity and use of non-ionizing radiations. Open ...
(Date:5/29/2015)... , May 28, 2015 Research and ... of Jain PharmaBiotech,s new report "Cardiovascular Drug ... their offering. Drug delivery to the ... systems because of the anatomy and physiology of ... to all organs of the body. Drugs can ...
(Date:5/29/2015)... , May 29, 2015 LifeNet Health ... total hiring for 2015 to more than 160 people. ... increased demand for LifeNet Health,s innovative bio-implants, which are ... more patients to be served. It also is a ... industry. "The growth and success of LifeNet ...
Breaking Medicine Technology:North America Open System MRI Market 2014-2019 with GE, Hitachi Medical, Philips Healthcare, Siemens Healthcare and Toshiba Medical Dominating 2Global Cardiovascular Drug Delivery Market 2015 - Technologies, Markets and Companies 2Global Cardiovascular Drug Delivery Market 2015 - Technologies, Markets and Companies 3LifeNet Health to add more than 160 jobs in 2015 2
(Date:5/30/2015)... 30, 2015 Cyclist Barry Haarde ... for the World 2015: Piles of Miles” near ... awareness about hemophilia and encourage individuals to support ... , Save One Life supports nearly 1,200 impoverished ... countries through direct sponsorships, scholarships and micro-enterprise grants. ...
(Date:5/30/2015)... The iconic American actor, and host of ... new segment on Medical Malpractice. This segment of “In ... the health care field. , According to the Bureau ... suits were filed, roughly only 20% of them made ... court, while the remaining 30% were tossed out. (Source: ...
(Date:5/30/2015)... Las Vegas, Nevada (PRWEB) May 30, 2015 ... effective treatment of acne scars, large pores, deep wrinkles, ... by a licensed medical professional, such as Dr. F. ... conducted some of the clinical trials in Las Vegas. ... and SmartScan technology into a system that delivers proven ...
(Date:5/29/2015)... St. Louis, MO (PRWEB) May 29, 2015 ... been selling autism awareness shirts for a couple ... start conversations. Their latest release, which reads “I’m not ... to be worn by the parent’s of an autistic child ... better understanding of autism. , Not only are they raising ...
(Date:5/29/2015)... Washington, PA (PRWEB) May 29, 2015 ... ” quiz-based learning in 14 medical specialties, now offers ... includes a wide spectrum of rheumatology disorders ranging from ... Alfred Saint Jacques, editorial director of MDLinx, and Caroline ... excited about the impact it will have on the ...
Breaking Medicine News(10 mins):Health News:Barry Haarde Cycles 4,000 Miles Across the USA for Hemophilia 2Health News:Announcing Ground-Breaking Technology for Anti-Aging, FDA Approved, Venus Viva. 2Health News:Announcing Ground-Breaking Technology for Anti-Aging, FDA Approved, Venus Viva. 3Health News:La La Land Shirts Is Busy Spreading Autism Awareness with Complimentary Shipping on Their New Shirt 2Health News:MDLinx Launches Smartest Rheumatologist 2
... Adding radiation and hormone treatment to brachytherapy improves survival, ... Men with aggressive prostate cancer who have brachytherapy alone ... a combination of treatments, new findings show. , In ... "Despite the increasing numbers of men worldwide who choose ...
... solely by better screening: study , TUESDAY, July 14 ... in thyroid cancers noted in the United States since 1980, ... blame. , A new study finds that thyroid tumors of ... ones that more aggressive screening would be expected to detect. ...
... , , , ... of Wyeth (NYSE: WYE ), announced today that the ... first government agency to approve Prevenar 13* Valent, (Pneumococcal Conjugate Vaccine ... 13 Valent is approved for active immunization of children aged 6 ...
... July 14 Northeast Health Care Quality Foundation, one of ... five-year licensing agreement with Milliman Care Guidelines, LLC, A Milliman ... utilization and quality reviews in Maine, New Hampshire and Vermont, ... , , Northeast Health Care Quality Foundation ...
... HARBIN, China, July 14 /PRNewswire-Asia-FirstCall/ ... Medical" or "the Company") (Nasdaq: CSKI ... in the People,s Republic of China ("PRC"), today ... ("Jin Chuang") subsidiary obtained a,renewal of its Good ...
... , , , BANNOCKBURN, ... days and warmer weather are afoot. The season is also notoriously a ... the gym can be daunting, especially with so many people pressed for ... to shape up for summer that,s accessible, affordable and can accommodate even ...
Cached Medicine News:Health News:Combination Therapy Best for Aggressive Prostate Cancer 2Health News:Increase in Thyroid Cancer Puzzles Experts 2Health News:Wyeth's Prevenar 13* Receives First Approval 2Health News:Wyeth's Prevenar 13* Receives First Approval 3Health News:Wyeth's Prevenar 13* Receives First Approval 4Health News:Wyeth's Prevenar 13* Receives First Approval 5Health News:Northeast Health Care Quality Foundation QIO Uses Milliman Care Guidelines(R) for Medicare, Medicaid Reviews 2Health News:Northeast Health Care Quality Foundation QIO Uses Milliman Care Guidelines(R) for Medicare, Medicaid Reviews 3Health News:China Sky One Medical, Inc. Obtains Renewal of GMP Certificate 2Health News:China Sky One Medical, Inc. Obtains Renewal of GMP Certificate 3Health News:Looking to Shape Up for Summer? The Solution May Be the Steps You're Already Taking 2Health News:Looking to Shape Up for Summer? The Solution May Be the Steps You're Already Taking 3
Hydraulic ophthalmic stretcher for eye surgery....
... a staining solution for cataract surgery. ... performing a safe phaco-emulsification procedure. Inadequate ... may result in an incomplete capsulorhexis, ... radial capsule tears and associated complications. ...
Rhex-ID (Trypan Blue 0.8 mg)....
Unmatched versatility for hemostasis wherever needed. Can be applied to suit your needs....
Medicine Products: